Pfizer, Amgen eye $1B deal for Russian biosimilars developer Biocad

Russian pharma dealmaking is heating up. On the heels of news that Pharmastandard is shopping its over-the-counter business, the biosimilar developer Biocad is said to be entertaining offers from the likes of Pfizer and Amgen. The Russian company could be worth as much as $1 billion, sources told Bloomberg. Story